Home   News   Article

£250,000 appeal success funds Addenbrooke’s new liver machine


By Adrian Curtis


Addenbrooke’s Charitable Trust (ACT) has reached its £250,000 liver transplant appeal target.

Last year, the trust purchased a new liver perfusion machine in the hope of raising the money.

The equipment, which has now been fully funded, allows surgeons to ‘test drive’ livers for quality before transplanting them.

Since the installation of the liver perfusion machine, the transplant team at Addenbrooke’s has tested 57 livers, of which 43 were able to be used.

The Organox liver perfusion machine Picture: Addenbrooke's (14970807)
The Organox liver perfusion machine Picture: Addenbrooke's (14970807)

Prof Christopher Watson, consultant transplant surgeon at Addenbrooke’s, said: “Having the machine allows Addenbrooke’s to use the greatest proportion of high-risk livers – those where subsequent function would otherwise be uncertain – than any other transplant centre in the UK.

“It also contributes to our having the best 30-day survival rate and the highest transplant rate per waiting list patient, meaning that fewer patients will die waiting for a liver.”

As more transplants are being carried out along with the forthcoming opt-out system for organ donation, ACT wants to ensure that the hospital is ready for this increased demand.



COMMENTS
()


Iliffe Media does not moderate comments. Please click here for our house rules.

People who post abusive comments about other users or those featured in articles will be banned.

Thank you. Your comment has been received and will appear on the site shortly.

 

Terms of Comments

We do not actively moderate, monitor or edit contributions to the reader comments but we may intervene and take such action as we think necessary, please click here for our house rules.

If you have any concerns over the contents on our site, please either register those concerns using the report abuse button, contact us here.

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies - Learn More